Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates

Scott A Reisman
Sarabjit S Gahir
Chun-Yue I Lee
Joel W Proksch
Mitsumasa Sakamoto
Keith W Ward
Reata Pharmaceuticals, Inc., Irving, TX 75063, USA

Background: Omaveloxolone is a synthetic oleanane triterpenoid that pharmacologically activates Nrf2, a master transcription factor that regulates genes with antioxidative, anti-inflammatory, and mitochondrial bioenergetic properties, and is being evaluated in patients with Friedreich’s ataxia.

Methods: The present study evaluated the pharmacokinetics (PK) and tissue distribution of omaveloxolone in monkeys after single and multiple oral doses, and then compared these data to initial results in Friedreich’s ataxia patients. Pharmacodynamic (PD) evaluations in monkeys consisted of Nrf2 target gene mRNA expression in peripheral blood mononuclear cells (PBMCs), liver, lung, and brain. A PK/PD model was generated with the monkey data, and used to further evaluate the Friedreich’s ataxia patient PK profile.

Results: Oral administration of omaveloxolone to monkeys was associated with dose-linear plasma PK and readily measureable and dose-proportional concentrations in liver, lung, and brain. Dose-dependent induction of Nrf2 target genes in PBMCs and tissues was also observed. Clinically, oral administration of omaveloxolone to Friedreich’s ataxia patients at incremental doses from 2.5 to 300 mg produced dose-proportional systemic exposures. Clinical doses of at least 80 mg were associated with meaningful improvements in neurological function in patients and generated plasma omaveloxolone concentrations consistent with those significantly inducing Nrf2 target genes in monkeys, as shown with the monkey PK/PD model.

Conclusion: Overall, the monkey data demonstrate a well-characterized and dose-proportional PK and tissue distribution profile after oral administration of omaveloxolone, which was associated with Nrf2 activation. Further, systemic exposures to omaveloxolone that produce Nrf2 activation in monkeys were readily achievable in Friedreich’s ataxia patients after oral administration.

Keywords: omaveloxolone, Nrf2, pharmacokinetics, Friedreich’s ataxia, Nqo1, ferritin, NADPH, glutathione

Introduction

Omaveloxolone (N-(2-Cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide; CDDO-DPFA; RTA 408), a semi-synthetic oleanane triterpenoid, is in a class of compounds known to be very potent activators of nuclear factor erythroid-derived 2-like 2 factor (Nrf2).\(^1\) Nrf2 regulates the expression of nearly all antioxidative enzymes, including the prototypical Nrf2 target gene NAD(P)H quinone:oxidoreductase 1 (Nqo1), as well as thioredoxin reductase 1 (Txnrd1), the peroxiredoxin regulator sulfiredoxin 1 (Srxn1), genes involved in glutathione homeostasis [eg, glutamate–cysteine ligase catalytic subunit (Gclc) and glutathione reductase (Gsr)], ald-keto reductase 1c1 (Akr1c1), and proteins important in iron homeostasis (eg, ferritin).\(^2\)\(^3\) Nrf2 also controls the expression of enzymes important in the pentose phosphate pathway and the production of NADPH, namely phosphogluconate.
ataxia, cardiomyopathy, and diabetes.

the three main symptoms of Friedreich’s ataxia, namely population leads to degeneration of dorsal root ganglia, neu

amics of RTA 408 in the Treatment of Friedreich’s Ataxia; ing in a Phase II trial in patients with Friedreich’s ataxia prevents neuronal cell death.

ATP and glutathione in the cortex and hippocampus, and dramatically decreases the frequency of seizures, increases shown to be critical for neuronal defense,

rat model of status epilepticus, where Nrf2 has also been from hypomagnesemia-induced cell death. Further, in a example, omaveloxolone protects cultured cortical neurons neuronal mitochondrial dysfunction and oxidative stress. For

efficacy in both in vitro and in vivo non-clinical models of neuronal mitochondrial dysfunction and oxidative stress. For example, omaveloxolone protects cultured cortical neurons with silenced frataxin and mice with a conditional frataxin knockout in heart and skeletal muscle have decreased Nrf2 activity. Thus, pharmacologically activating Nrf2 has the potential to be beneficial in patients with Friedreich’s ataxia and possibly other neurological disorders. Importantly, the Nrf2 activator omaveloxolone has demonstrated efficacy in both in vitro and in vivo non-clinical models of neuronal mitochondrial dysfunction and oxidative stress. For example, omaveloxolone protects cultured cortical neurons from hypomagnesemia-induced cell death. Further, in a rat model of status epilepticus, where Nrf2 has also been shown to be critical for neuronal defense, omaveloxolone dramatically decreases the frequency of seizures, increases ATP and glutathione in the cortex and hippocampus, and prevents neuronal cell death.

Currently, omaveloxolone is undergoing clinical test-
ing in a Phase II trial in patients with Friedreich’s ataxia (A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich’s Ataxia; MOX1e; NCT02255435). A lack of frataxin in this patient population leads to degeneration of dorsal root ganglia, neu-

nors, cardiac myocytes, and pancreatic beta cells, causing the three main symptoms of Friedreich’s ataxia, namely ataxia, cardiomyopathy, and diabetes. Moreover, recent

in vitro work suggests that the mechanism of action of omaveloxolone is directly applicable to the pathophysiology of Friedreich’s ataxia. Indeed, encouraging results, in the form of improved neurological and mitochondrial function, and increases in Nrf2 biomarkers (eg, ferritin), were observed in the first part of a Phase II clinical trial in Friedreich’s ataxia patients.

This study was conducted to evaluate the pharmacokinetic (PK) profile and tissue distribution of omaveloxolone and characterize its effects in selected tissues on Nrf2 target gene mRNA expression in monkeys after oral administration. The plasma concentration–time profile of omaveloxolone and its effects on Nrf2 target gene mRNA expression in peripheral blood mononuclear cells (PBMCs) were used to build a pharmacokinetic/pharmacodynamic (PK/PD) model. In addition, the plasma exposure and PK profile observed in the ongoing Phase II clinical trial with omaveloxolone in Friedreich’s ataxia patients (NCT02255435) are described and compared with the output from the monkey PK/PD model to estimate the dose levels in patients that are predicted to increase Nrf2 target gene expression.

Methods

Materials

Omaveloxolone was supplied by Reata Pharmaceuticals (Irving, TX, USA). Unless otherwise specified, other chemicals were of analytical grade and obtained from Sigma-Aldrich (St Louis, MO, USA) or another major commercial supplier.

Monkey (in vivo) studies

To determine omaveloxolone PK, male and female cynomol-gus monkeys (n=5/sex/dose group) received omaveloxolone at 10, 30, or 100 mg/kg/day by oral gavage in sesame oil (5 mL/kg) with collection of blood through 24 hours after a single administration or after 28 days of once-daily administrations. For tissue content and mRNA expression analyses, male and female cynomolgus monkeys (n=2/sex/dose group) received omaveloxolone at 10, 30, or 100 mg/kg/day or vehicle (sesame oil, 5 mL/kg) by oral gavage once daily for 14 days. On day 14, 24 hours after the final dose, monkeys were euthan-

ized. Tissues (liver, lung, and brain) were collected, rinsed with PBS, dry-blotted, and frozen in liquid nitrogen. Blood samples were also collected for analysis of corresponding omaveloxolone concentrations in plasma. Blood for plasma bioanalysis was collected into tubes containing K<sub>3</sub>EDTA as the anticoagulant and supplemented with sodium sulfite (0.25%, final concentration) to prevent oxidative degradation.
of omaveloxolone. All plasma and tissue samples were stored at approximately −80°C until analysis.

In a separate study, male and female cynomolgus monkeys (n=3/sex/dose) received a single oral administration of omaveloxolone at 10, 30, and 100 mg/kg/day or vehicle (sesame oil, 5 mL/kg) by oral gavage. Blood was collected pre-dose and 4, 8, 12, and 24 hours post-dose for isolation of PBMCs and plasma. PBMCs were isolated using CPT tubes (catalog number 362760; BD Biosciences, San Jose, CA, USA). The PBMCs were used for mRNA expression analyses, and the plasma was used for determination of corresponding concentrations of omaveloxolone. All monkey studies were performed as per approved protocols by the Institutional Animal Care and Use Committee at the site where the in vivo portion of the study was conducted (MPI Research, Mattawan, MI, USA). Animal welfare was in compliance with the US Department of Agriculture’s (USDA) Animal Welfare Act (9 CFR Parts 1, 2, and 3). Further, the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy Press, Washington, DC, 1996) was followed.

Clinical study
Part 1 of the clinical study MOXIe (https://www.clinicaltrials.gov/ct2/show/NCT02255435) was a randomized, placebo-controlled, double-blind, dose-escalation study to evaluate the safety of omaveloxolone at various doses in patients with Friedreich’s ataxia. Patients were randomized to omaveloxolone at the specific cohort dose with five or six patients on active drug and two on placebo for all dose groups except the 160-mg dose group, where 12 patients were on active drug and four on placebo. Patients in the first cohort received 2.5 mg for 2 weeks and then were escalated to 5 mg for the next 10 weeks. Patients in the subsequent cohorts received oral doses of placebo or omaveloxolone capsules at 10, 20, 40, 80, 160, or 300 mg once daily for 12 weeks. Blood samples were collected (with K₂EDTA as the anticoagulant) at a presumed steady state for PK analysis after 2 weeks of daily dosing (for all dose groups except the 5 mg dose group, which was collected at a presumed steady state after 8 weeks of daily dosing) at pre-dose and 1, 2, 4, and 8 hours after dose administration. Because the PK collection occurred at steady state, the pre-dose plasma concentration was imputed to the 24-hour time-point for the purposes of exploratory PK analyses. After blood collection and centrifugation, plasma was transferred to cryovials containing sodium sulfite (final concentration 0.25%) to prevent oxidative degradation and stored at approximately −80°C until analysis. The clinical study was designed and implemented in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6(R1) guidance, with applicable local regulations (eg, US CFR Title 21), and with the ethical principles of the Declaration of Helsinki. All participants provided written informed consent prior to participating in the study. Study approval was obtained for each site by an institutional review board or ethics committee, as appropriate. A tabulated list of the institutional review boards and ethics committees can be found in Table S1. For this study, the de-identified participant data, protocol, and the statistical analysis plan will not be shared for external analysis.

Omaveloxolone quantification in plasma and tissues
Omaveloxolone was extracted from monkey and human plasma and then quantified using liquid chromatography–tandem mass spectrometry (LC-MS/MS) methodology, similarly to methods described previously.17,18 Plasma calibration curves were prepared in the appropriate species biomat and supplemented with 0.25% sodium sulfite to prevent oxidative degradation of omaveloxolone.

Omaveloxolone was extracted from monkey tissues using a liquid–liquid extraction technique. The tissues from monkeys were homogenized in ice-cold PBS (500 mg/mL) and then mixed well with acetonitrile supplemented with 0.2% formic acid (200 μL). Methyl tert-butyl ether (5 mL) was then added to the samples, which were then vortexed for 5 minutes and centrifuged for 10 minutes at 2,100 × g. The supernatant was transferred and placed on a heat block (40°C) under a gentle stream of nitrogen gas to evaporate to dryness. The extracted samples were reconstituted with 150 μL acetonitrile, and 7.5 μL was injected for LC-MS/MS analysis. Omaveloxolone was quantified using a Waters Acquity UPLC system (Milford, MA, USA) coupled to a Waters TQD mass spectrometer using an Acquity UPLC BEH Phenyl column (catalog number 18600450). The mobile phases consisted of 0.2% formic acid in water (v/v) and 100% acetonitrile run on a gradient over 2.80 minutes. The MS/MS was run using electrospray ionization in positive ion multiple reaction monitoring mode with omaveloxolone detected at m/z 555.4→446.3. Calibration standards spanning a dynamic range of concentrations were prepared volumetrically in appropriate naïve monkey biomatrices and processed in a similar way to the samples. Samples from vehicle-treated monkeys were also analyzed (data not shown) and considered to be zero for subsequent analyses.
PK parameter estimates
PK parameter estimates were obtained by non-compartmental analysis of the individual omaveloxolone plasma concentration–time data using WinNonlin™ software version 6.2.1 (Pharsight Corp., Cary, NC, USA). The area under the plasma concentration–time curve from time 0 to 24 hours (AUC_{(0-24h)}) was determined using the linear trapezoidal–linear interpolation method in monkeys and the linear up–log down method in humans. The presented clinical PK parameters are based on interim PK data, and calculated using nominal time-points.

mRNA quantification
mRNA was quantified, as previously described, using the Quantigene™ Plex 2.0 assay from Affymetrix (Santa Clara, CA, USA).19 Panels with targets designed against the human genome were used. Further details for the design of the panels can be found at https://www.thermofisher.com/order/quantigene-plex/configuration. The mRNA expression data were standardized to the internal control ribosomal protein L13A (RPL13A) and presented as fold the mean vehicle control ± SEM.

PK/PD modeling
Population PK/PD analysis was performed using monkey plasma omaveloxolone concentration data and mRNA expression fold changes from baseline in monkey PBMCs. PK/PD analyses were conducted with Phoenix NLME software (Build 8.0.0.3176), and a nonlinear mixed effects model was developed. The modeling was conducted in two stages, beginning with fitting a PK model to the data, and then incorporating the PD data to generate a final PK/PD model. The QRPEM engine was employed for fitting the model to the data.

Statistics
Plasma omaveloxolone concentration and PK data are presented as the mean ± SD. mRNA expression data are presented as mean ± SEM, with the data analyzed by one-way or two-way ANOVA followed by Duncan’s multiple range or Dunnett’s multiple comparisons post-hoc test, where appropriate, with p-values <0.05 considered statistically significant.

Results
Summary of omaveloxolone non-clinical and clinical PK profiles
After a single oral administration to monkeys, near-maximal omaveloxolone concentrations in plasma were observed within 1 hour, and measurable concentrations were observed through 24 hours (Figure 1). Systemic exposures to omaveloxolone, based on peak plasma concentrations (C_{max}) and AUC, increased dose-proportionally (Table 1). Peak omaveloxolone concentrations after a single dose in monkeys occurred between 8 and 12 hours (T_{max}), and the apparent terminal half-life ranged from approximately 9 to 18 hours. There were no meaningful differences in PK profiles between males and females (data not shown), and exposures (based on AUC) following repeated daily oral administration for 28 days tended to be slightly higher (<2-fold change) than the exposures observed after a single administration. After repeated daily administration, the T_{max} at steady state was between 2 and 4 hours, and the variability

![Figure 1](https://www.dovepress.com/DrugDesignDevTherapy.com/DrugDesignDevTherapy.com.1262/)  
**Figure 1** Representative omaveloxolone plasma concentration–time profiles in monkeys on day 1 and day 28.  
**Notes:** Left panel: Blood was collected after a single oral dose of omaveloxolone (10, 30, or 100 mg/kg) to cynomolgus monkeys (n=5/sex/dose group) pre-dose and at various time-points through 24 hours post-dose. Right panel: Blood was collected after 28 days of once-daily oral dosing of omaveloxolone (10, 30, or 100 mg/kg/day) to the same cynomolgus monkeys (n=5/sex/dose group) pre-dose and at various time-points through 24 hours post-dose. Plasma concentrations of omaveloxolone were determined using liquid chromatography–tandem mass spectrometry methodology. Data are presented as mean omaveloxolone plasma concentrations ± SD.
in half-life decreased compared to the single-dose data with approximate values in the 8–12-hour range (Table 1).

Next, clinical PK data obtained following daily oral administration of omaveloxolone capsules to Friedreich’s ataxia patients were analyzed (Figure 2A and Table 2). At the presumed steady state, omaveloxolone demonstrated dose-dependent and linear PK over a dose range of 2.5–300 mg, based on both $C_{\text{max}}$ and AUC. Omaveloxolone

<p>| Table 1 Omaveloxolone PK parameters for cynomolgus monkeys |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Parameter (units)</th>
<th>Day 1</th>
<th>Day 28</th>
<th>Day 1</th>
<th>Day 28</th>
<th>Day 1</th>
<th>Day 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose (mg/kg)</td>
<td>10</td>
<td>30</td>
<td>100</td>
<td>10</td>
<td>30</td>
<td>100</td>
</tr>
<tr>
<td>N</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (hours)</td>
<td>10</td>
<td>12</td>
<td>8</td>
<td>2</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (ng/mL)</td>
<td>44.8±49.7</td>
<td>105±34</td>
<td>227±177</td>
<td>54.8±13.7</td>
<td>213±44</td>
<td>358±86</td>
</tr>
<tr>
<td>AUC$_{(0-24\ h)}$ (h×μg/mL)</td>
<td>0.502±0.315</td>
<td>1.74±0.46</td>
<td>3.16±0.71</td>
<td>0.681±0.144</td>
<td>2.76±0.58</td>
<td>5.68±1.29</td>
</tr>
<tr>
<td>AUC$_{(0-24\ h)}$/Dose (h×μg/mL)/(mg/kg)</td>
<td>0.0502</td>
<td>0.0581</td>
<td>0.0316</td>
<td>0.0681</td>
<td>0.0918</td>
<td>0.0568</td>
</tr>
<tr>
<td>D28 AUC/D1 AUC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.36</td>
<td>1.59</td>
<td>1.80</td>
</tr>
<tr>
<td>$T_{1/2}$ (hours)</td>
<td>8.74±2.56</td>
<td>11.0±4.8</td>
<td>18.1±6.8</td>
<td>9.56±5.49</td>
<td>8.24±2.59</td>
<td>12.2±4.2</td>
</tr>
</tbody>
</table>

Notes: PK parameter estimates were determined for each individual monkey and are presented as mean ± SD. $T_{\text{max}}$ data are presented as median.

Abbreviations: AUC, area under the curve; $C_{\text{max}}$, maximum plasma concentration; D, day; PK, pharmacokinetic; $T_{1/2}$, terminal half-life; $T_{\text{max}}$, time to maximum plasma concentration.

Figure 2 Omaveloxolone pharmacokinetic profile in Friedreich’s ataxia patients.

Notes: Blood was collected from Friedreich’s ataxia patients (n=5 or 6 for all dose groups except the 160-mg dose group, which was n=12) after once-daily dosing for 2 weeks for all dose groups except the 5-mg dose group (8 weeks of once-daily dosing) at pre-dose and at 1, 2, 4, and 8 hours post-dose. Because the blood samples were collected at steady state, the measured concentration in the pre-dose sample was imputed for the 24-hour time-point. (A) Omaveloxolone plasma concentration–time profiles. Data are presented as mean omaveloxolone plasma concentrations ± SD. (B) Individual AUC vs body-weight normalized dose with a linear trend line and 95% CIs. (C) Individual $C_{\text{max}}$ vs body-weight normalized dose with a linear trend line and 95% CIs.

Abbreviations: AUC, area under the curve; $C_{\text{max}}$, maximum plasma concentration.
also demonstrated relatively low interpatient variability (Figure 2B and C) with mean %CV across dose groups of approximately 31% for AUC values and approximately 43% for C<sub>max</sub> values. A 160-mg dose was associated with evidence of clinical activity, including improvements in neurological function as assessed by modified Friedreich’s Ataxia Rating Scale (mFARS) scores after 12 weeks of dosing in Part 1 of the Phase II clinical trial.<sup>16</sup>

The clinical activity observed at the 160-mg dose was also associated with changes in serum biomarkers of Nrf2 pharmacological activity (eg, increased ferritin and decreased creatine kinase). The relatively low interpatient variability and dose-proportional PK observed for omaveloxolone in Part 1 of the clinical trial were important for selection of the final dose after 2 weeks of daily oral administration of omaveloxolone (10, 30, and 100 mg/kg) and analyzed for mRNA expression of various Nrf2 target genes (Figure 4). Omaveloxolone significantly and dose-dependently induced a variety of Nrf2 target genes in liver and lung. In brain, there was a trend for some Nrf2 target genes (ie, NQO1, SRXN1, and TXNRD1) to increase with dose, but only GSR

**Table 2 Omaveloxolone PK parameters for Friedreich’s ataxia patients**

<table>
<thead>
<tr>
<th>Dose (mg)</th>
<th>N</th>
<th>Body weight (kg)</th>
<th>Dose (mg/kg)</th>
<th>T&lt;sub&gt;max&lt;/sub&gt; (hours)</th>
<th>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</th>
<th>AUC (0–24 h) (h×ng/mL)</th>
<th>AUC (0–24 h)/Dose ([h×ng/mL]/[mg/kg])</th>
<th>T&lt;sub&gt;1/2&lt;/sub&gt; (hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6</td>
<td>64.4±14.3</td>
<td>0.040±0.0081</td>
<td>2</td>
<td>2.20±0.94</td>
<td>0.018±0.0064</td>
<td>0.458±0.126</td>
<td>17.4±7.6</td>
</tr>
<tr>
<td>5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6</td>
<td>66.7±14.6</td>
<td>0.077±0.0162</td>
<td>2</td>
<td>5.1±3.55</td>
<td>0.033±0.0157</td>
<td>0.493±0.210</td>
<td>14.7±3.6</td>
</tr>
<tr>
<td>10&lt;sup&gt;c&lt;/sup&gt;</td>
<td>6</td>
<td>72.8±28.7</td>
<td>0.151±0.042</td>
<td>2</td>
<td>10±4.8</td>
<td>0.13±0.053</td>
<td>0.948±0.376</td>
<td>20.6±19.4</td>
</tr>
<tr>
<td>20&lt;sup&gt;d&lt;/sup&gt;</td>
<td>5</td>
<td>56.5±5.0</td>
<td>0.356±0.033</td>
<td>2</td>
<td>18±6.4</td>
<td>0.225±0.043</td>
<td>0.630±0.085</td>
<td>18.3±1.6</td>
</tr>
<tr>
<td>40&lt;sup&gt;e&lt;/sup&gt;</td>
<td>6</td>
<td>78.3±20.0</td>
<td>0.541±0.144</td>
<td>2</td>
<td>24.9±6.6</td>
<td>0.326±0.627</td>
<td>0.639±0.211</td>
<td>16.8±7.7</td>
</tr>
<tr>
<td>80&lt;sup&gt;f&lt;/sup&gt;</td>
<td>6</td>
<td>64.6±5.2</td>
<td>1.25±0.10</td>
<td>3</td>
<td>48±26.6</td>
<td>0.627±0.250</td>
<td>0.496±0.182</td>
<td>15.0±4.6</td>
</tr>
<tr>
<td>160&lt;sup&gt;g&lt;/sup&gt;</td>
<td>12</td>
<td>68.1±12.0</td>
<td>2.14±0.38</td>
<td>2</td>
<td>112±52</td>
<td>1.26±0.37</td>
<td>0.55±0.253</td>
<td>21.0±9.0</td>
</tr>
<tr>
<td>300&lt;sup&gt;h&lt;/sup&gt;</td>
<td>5</td>
<td>86.8±18.5</td>
<td>3.57±0.68</td>
<td>2</td>
<td>162±35</td>
<td>2.08±0.52</td>
<td>0.59±0.139</td>
<td>16.4±5.8</td>
</tr>
</tbody>
</table>

Notes: Values represent mean ± SD except for T<sub>max</sub> where median values are shown. PK samples were collected at 0, 1, 2, 4, and 8 hours; for the purposes of calculating PK parameter values it was assumed that the concentration at 24 hours was identical to the concentration at 0 hours (steady state). Data for the 2.5-mg dose obtained from cohort 1 at week 2 prior to intrapatient dose escalation. Data for the 5-mg dose obtained from cohort 1 at week 8 (ie, 6 weeks after intrapatient dose escalation from 2.5 mg).

**Abbreviations:** AUC, area under the curve; C<sub>max</sub>, maximum plasma concentration; PK, pharmacokinetic; T<sub>1/2</sub>, terminal half-life; T<sub>max</sub>, time to maximum plasma concentration.

higher than concentrations observed in plasma and, overall, demonstrated that omaveloxolone easily distributes to key tissues.

**Induction of Nrf2 target gene mRNA expression by omaveloxolone in tissues and PBMCs**

Monkey liver, lung, and brain were collected 24 hours after the final dose after 2 weeks of daily oral administration of omaveloxolone (10, 30, and 100 mg/kg) and analyzed for mRNA expression of various Nrf2 target genes (Figure 4). Omaveloxolone significantly and dose-dependently induced a variety of Nrf2 target genes in liver and lung. In brain, there was a trend for some Nrf2 target genes (ie, NQO1, SRXN1, and TXNRD1) to increase with dose, but only GSR

![Figure 3](https://www.dovepress.com/)

**Figure 3** Tissue distribution of omaveloxolone in monkeys after repeated administration.

**Notes:** Plasma and tissues were collected after 2 weeks of once-daily oral administration of omaveloxolone to cynomolgus monkeys (n=2/sex/dose group) at the indicated doses. Plasma and tissues were collected 24 hours following the final dose, and plasma concentrations and tissue content of omaveloxolone were quantified using liquid chromatography–tandem mass spectrometry methodology. Data are presented as mean omaveloxolone plasma concentration (or tissue content) ± SD.

**Omaveloxolone distributes to liver, lung, and brain**

The distribution of omaveloxolone to liver, lung, and brain was investigated in monkeys after daily oral administration for 14 days (Figure 3). Lung, liver, and brain displayed dose-dependent omaveloxolone content that was slightly

![Figure 2](https://www.dovepress.com/)

**Figure 2** A, Relative changes in ferritin (F) and ferritin-like protein (FLP) from baseline (week 0) for the 5-mg dose tested in Part 1 of the clinical trial. B, Relative changes in ferritin (F) and ferritin-like protein (FLP) from baseline (week 0) for the 160-mg dose tested in Part 2. C, Relative changes in serum creatine kinase (CK) from baseline (week 0) for the 5-mg dose tested in Part 1 of the clinical trial.
and AKR1C1 demonstrated statistical significance in the 100-mg/kg/day dose group.

PBMCs were collected from monkeys over a period of 24 hours for analysis of Nrf2 target gene mRNA expression after a single oral dose of omaveloxolone and compared to plasma concentrations of omaveloxolone collected at the same time-points. In general, omaveloxolone significantly and dose- and concentration-dependently induced the mRNA expression of Nrf2 target genes in liver, lung, and brain from monkeys.
expression of NQO1, SRXN1, TXNRD1, GSR, and PGD in PBMCs (Figure 5).

PK/PD modeling of monkey data
Population PK/PD analysis was performed on the data using nonlinear mixed-effect modeling. A PK model was first optimized prior to performing PK/PD modeling. The PK data were best described by a one-compartment model with residual additive error, and the model was fitted using the QRPEM engine. The optimized PK model was then used together with the PBMC mRNA expression data for NQO1, SRXN1, TXNRD1, GSR, and PGD to generate a PK/PD model.
Omaveloxolone demonstrated consistent dose-proportional and linear systemic exposures (based on $C_{\text{max}}$ and AUC) in both monkeys and humans. The PK profile determined in Friedreich’s ataxia patients was similar to the PK parameters (ie, AUC, $C_{\text{max}}$, and half-life) observed after oral administration of omaveloxolone to cancer patients in a previous Phase I study. Further, the mean apparent terminal half-life (range of 15–21 hours) of omaveloxolone in Friedreich’s ataxia patients supports a once-daily oral dosing regimen and appears to provide pharmacologically relevant exposures.

Regarding tissue distribution after oral administration in monkeys, omaveloxolone achieves meaningful concentrations in key tissues that are important in various disease pathologies, such as liver, lung, and brain. In addition, the tissue content of omaveloxolone is dose proportional, with concentrations in brain and lung that are similar to plasma concentrations. Thus, based on the monkey tissue distribution data, it is hypothesized that plasma omaveloxolone concentrations in humans may be comparable to tissue concentrations in the brain and other tissues in humans.

Selected Nrf2 target genes were dose-dependently and significantly induced in the evaluated monkey tissues, including brain. However, despite more than adequate brain penetration of omaveloxolone after oral dosing in monkeys, induction of the subset of Nrf2 target genes evaluated in the brain in this study was not as robust as in other tissues. It is noteworthy that previous studies have demonstrated the capacity of neurons for strong Nrf2 activation and induction of potentially hundreds of Nrf2 target genes in the brain, although lower in magnitude than in other tissues, may have significant biological effects. On the other hand, it is also possible that indiscriminate homogenization of parts of the brain where Nrf2 is not as responsive or as highly expressed with areas where Nrf2 is more responsive may have diluted the mRNA concentration of targets, thereby artifactually showing less robust change in mRNA expression.

Further, omaveloxolone also elicited concentration-dependent induction of Nrf2 target genes in PBMCs isolated from monkey blood. A PK/PD model was developed to characterize the relationship between omaveloxolone concentrations in plasma and the corresponding changes in Nrf2 target gene mRNA expression in PBMCs. From the monkey PK/PD model, tvEC$_{50}$ values were determined for several prototypical Nrf2 target genes and were compared with the omaveloxolone concentrations achieved in plasma from Friedreich’s ataxia patients in the Phase II study. From this comparison, it was concluded that robust Nrf2 target gene mRNA induction would be expected in patient PBMCs at omaveloxolone doses of 80 mg and above. To minimize blood collections and patient burden, PBMCs were not collected from the Friedreich’s ataxia patients in the Phase II trial; however, significant induction of Nrf2 target genes in PBMCs isolated from cancer patients treated with omaveloxolone has been observed previously. After oral administration of omaveloxolone in cancer patients, evidence of Nrf2 target gene induction was observed at doses in the range of 5–10 mg (the highest dose tested), with no clear effects at

Figure 6 Monkey PK/PD model overlaid with omaveloxolone plasma concentrations from Friedreich’s ataxia patients. Notes: Omaveloxolone $C_{\text{max}}$ data from individual Friedreich’s ataxia patients are plotted by dose. The monkey tvEC$_{50}$ values for SRXN1, NQO1, TXNRD1, PGD, and GSR PBMC mRNA expression determined via a PK/PD model, using Phoenix NLME software (Build 8.0.0.3176), are plotted along the y-axis. The black lines among the individual dots are representative of the mean $C_{\text{max}}$ values for each dose group.

Abbreviations: PD, pharmacodynamic; PK, pharmacokinetic; tvEC$_{50}$, typical half-maximal effective concentration values of the population.

Discussion

Omaveloxolone demonstrated consistent dose-proportional and linear systemic exposures (based on $C_{\text{max}}$ and AUC) in both monkeys and humans. The PK profile determined in Friedreich’s ataxia patients was similar to the PK parameters (ie, AUC, $C_{\text{max}}$, and half-life) observed after oral administration of omaveloxolone to cancer patients in a previous Phase I study. Further, the mean apparent terminal half-life (range of 15–21 hours) of omaveloxolone in Friedreich’s ataxia patients supports a once-daily oral dosing regimen and appears to provide pharmacologically relevant exposures.
ceptibility to oxidative stress are thought to contribute to the pathophysiology of Friedreich’s ataxia. Most applicable to the clinical development of omaveloxolone, recent non-clinical data have demonstrated that omaveloxolone affords significant protection from hydrogen peroxide-induced oxidative stress in cerebellar granule neurons collected from two different Friedreich’s ataxia mouse models (ie, KIKO and YG8R mice), as well as in fibroblasts collected from patients. Notably and in concurrence with protection from oxidative stress, omaveloxolone significantly induced glutathione concentrations and promoted mitochondrial respiration, two functional outputs known to be directly regulated by Nrf2. Further, the antioxidative and bioenergetic activity of omaveloxolone observed in cells collected from Friedreich’s ataxia patients suggests that Friedreich’s ataxia patients have the capacity to activate Nrf2 in response to omaveloxolone therapy.

In the current study, omaveloxolone readily distributed to important tissues in monkeys after oral dosing and induced Nrf2 target genes, including Nqo1, redoxins, and those involved in glutathione homeostasis, which are all diminished in patients with Friedreich’s ataxia. In conclusion, the present data characterize the PK of omaveloxolone after oral administration to monkeys and humans, and provide a preclinical PK/PD-based rationale to support Nrf2 target engagement in Friedreich’s ataxia patients and the evaluation of a 150-mg dose of omaveloxolone in Part 2 of the MOXl clinical trial.

Disclosure
All authors are employed by and have a financial interest in Reata Pharmaceuticals, Inc., the company developing omaveloxolone for the marketplace. The authors report no other conflicts of interest in this work.

References


### Supplementary material

**Table S1** List of institutional review boards and ethics committees for the MOXle clinical trial (NCT02255435)

<table>
<thead>
<tr>
<th>Country</th>
<th>Name and address of committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>Emory University IRB&lt;br&gt;1599 Clifton Rd, 5th floor&lt;br&gt;Atlanta, GA 30322, USA</td>
</tr>
<tr>
<td>USA</td>
<td>Western IRB&lt;br&gt;10139 39th Ave SE, Suite 120&lt;br&gt;Puyallup, WA 98374-2115, USA</td>
</tr>
<tr>
<td>USA</td>
<td>The Committees for the Protection of Human Subjects (IRB)&lt;br&gt;Children’s Hospital of Philadelphia&lt;br&gt;Roberts Center for Pediatric Research&lt;br&gt;2610 South Street, 4th floor&lt;br&gt;Philadelphia, PA 19146, USA</td>
</tr>
<tr>
<td>Australia</td>
<td>The Royal Children’s Hospital Human Research Ethics Committee&lt;br&gt;50 Flemington Road&lt;br&gt;Parkville, VIC, Australia 3052</td>
</tr>
<tr>
<td>Austria</td>
<td>Ethics Committee, Medical University Innsbruck&lt;br&gt;Innrain 43, 1st floor&lt;br&gt;Innsbruck, Tirol, Austria 6020</td>
</tr>
</tbody>
</table>